Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.39 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL246032 | 0.98 | HTR2A (0.58) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL28158895 | 0.96 | HTR2A (0.56) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Iodide SCHEMBL4110593 | 0.96 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8861752 | 0.96 | HTR2A (0.60) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL8909571 | 0.94 | HTR2A (0.53) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL8782143 | 0.92 | HTR2A (0.52) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL9147651 | 0.91 | HTR2A (0.50) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9549516 | 0.90 | HTR2A (0.53) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 | |
| Bromide SCHEMBL143506 | 0.88 | HIF1A (0.58) | HTR2AHRH1HIF1ACYP1A2CYP2D6 | |
| Acetic Acid SCHEMBL9549706 | 0.86 | HTR2A (0.50) | HTR2AHRH1HIF1ASIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708284-B2 | Process for the preparation of olopatadine and sylil intermediates thereof | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2017-07-18 | — | — | US | claimed |
| CN-105849095-A | A process for the preparation of olopatadine and sylil intermediates thereof | 化学实验室国际股份公司 | 2016-08-10 | — | — | CN | claimed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | claimed |
| EP-2666770-A1 | Process for obtaining olopatadine and intermediates | Crystal Pharma S.A.U (ES) | 2013-11-27 | — | — | EP | claimed |
| EP-2145882-B1 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA SAU (ES) | 2013-08-21 | — | — | EP | claimed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | claimed |
| JP-2011528017-A | — | — | 2011-11-10 | — | — | JP | claimed |
| WO-2011128911-A2 | IMPROVED PROCESS FOR LL-[(Z)-3-(DIMETHYLAMINO)PROPYIIDENEL-6-LL- DIHYDRODIBENZ[B,EL OXEPIN-2-ACETICACID | MSN LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | WO | claimed |
| WO-2010007056-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2010-01-21 | — | — | WO | claimed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5760809-A | INK JET PRINTING | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0615853-B1 | Recording sheets containing phosphonium compounds | XEROX CORP (US) | 1996-10-16 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0615853-A1 | Recording sheets containing phosphonium compounds | XEROX CORPORATION (US) | 1994-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | OXER1, AOC3, OPRD1 | CHRM2 29/4885CHRM4 124/4885CHRM5 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.